Among the many ways Trump has shattered White House norms, his impulsive public communications rank among the most consequential. By inspiring investors or spooking them, his...Politicsread more
A federal judge in New York City on Wednesday said Deutsche Bank and Capital One can turn over financial documents related to President Donald Trump and his businesses in...Politicsread more
CNEX, backed by Microsoft and Dell, filed new allegations in a Texas suit accusing China's Huawei and an executive of trade secrets theft.Technologyread more
In a private call with Morgan Stanley clients on Wednesday, research analyst Adam Jones, a long-time Tesla bull, said it's extremely unlikely that big tech firms like Apple or...Technologyread more
Shares of L Brands, the owner of Victoria's Secret and Bath & Body Works, rose nearly 11% in aftermarket trading Wednesday after the company reported it beat revenue and...Retailread more
Officials remained firmly committed to a "patient" policy stance at their meeting earlier this month.The Fedread more
The president may have more success in the court fights to come, including appeals in the cases decided this week. But the two losses are nonetheless a dramatic setback for...Politicsread more
"Target's gutsy decision to make its stores the centerpiece of its fulfillment system has turned out to be a brilliant move," Jim Cramer says.Mad Money with Jim Cramerread more
A slew of retail earnings the past two weeks makes it clear that while Americans continue to shop, they aren't ringing registers at department stores.Retailread more
Talk about 5G is everywhere right now, from the trade war with China to the ban on Huawei. Here's what 5G is and why it matters.Technologyread more
Stocks that would benefit from a federal infrastructure spending program fell after President Trump ended a meeting on infrastructure spending with Democratic leaders.Market Insiderread more
The Food and Drug Administration will try to prevent major pharmaceutical companies from playing "regulatory arbitrage" in the generic drug business, the agency's commissioner, Dr. Scott Gottlieb, told CNBC on Wednesday.
"We don't play a role in drug pricing, but we do affect drug competition in terms of getting new drugs on to the market, and create competition to older drugs, particularly with generic drugs," Gottlieb said on "Squawk Box. "
When asked directly how the FDA plans to deal with situations like ex-pharma CEO Martin Shkreli's raising of a lifesaving drug by 5,000 percent, Gottlieb said, "There's a second set of policies ... that I think would prevent the ability of people to come in and pick off low-volume generic drugs, where there might not be a lot of competitors because they're just not used a lot, and raise the price and basically take advantage of regulatory arbitrage, where it might take a year or more to get another generic copy to the market."
Major drugmakers have been scrutinized for hefty price increases, especially after the outrage that stemmed from Shkreli's 2015 hike of the cost of Daraprim, a drug used to treat a certain kind of infection that's particularly dangerous for people who have weakened immune systems, such as AIDS patients and pregnant women. He later walked back the price increase.
Shkreli is currently standing trial, with jury selection underway this week, on charges of securities fraud unrelated to the Daraprim scandal. He has pleaded not guilty.
Gottlieb spoke to CNBC as Republican lawmakers are focused on trying to replace the Affordable Care Act, better known as Obamacare. But he said the FDA wants to focus on getting more low-cost generic drugs on the market faster to help ease the financial burden on American consumers.
According to the FDA, not every drug has a generic. Most drug companies have a patent on their medications, and once that patent expires, competitors can start selling a generic version of the drug.
"There are various techniques branded companies sometimes employ to block the generic companies from getting access to the samples that they need. One of them is taking advantage of certain rules the FDA puts in place to manage the risk of drugs in the post market, so-called risk management plans," he said.
Gottlieb said the FDA is publishing a list of where there is only one drug on the market. He said the agency is also going to prioritize the entry of new generic drugs into each category until there are three competitors.
"We really don't see the big price breaks for consumers until there are three competitors in the marketplace," the commissioner said. "We have to facilitate competition."
— Reuters contributed to this report.